Compare GPRO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | PRQR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | Netherlands |
| Employees | 636 | 187 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 190.5M |
| IPO Year | 2014 | 2014 |
| Metric | GPRO | PRQR |
|---|---|---|
| Price | $0.90 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.78 |
| AVG Volume (30 Days) | ★ 6.1M | 965.3K |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $651,542,000.00 | N/A |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | $35.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $1.20 |
| 52 Week High | $2.05 | $2.49 |
| Indicator | GPRO | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 32.75 | 41.56 |
| Support Level | $0.68 | $1.20 |
| Resistance Level | $1.17 | $1.54 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 14.94 | 50.00 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.